1 – 27 of 27
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)
(
- Contribution to journal › Article
- 2022
-
Mark
Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia
(
- Contribution to journal › Article
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
- 2019
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
- 2018
-
Mark
Morphological and hemodynamical alterations in brachial artery and cephalic vein. An image-based study for preoperative assessment for vascular access creation
(
- Contribution to journal › Article
-
Mark
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia
(
- Contribution to journal › Article
- 2017
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
- 2016
-
Mark
A Small Molecule Pyrazolo[3,4-d]pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle.
(
- Contribution to journal › Article
-
Mark
ANCA-associated glomerulonephritis : Risk factors for renal relapse
(
- Contribution to journal › Article
-
Mark
The genomic landscape of core-binding factor acute myeloid leukemias
(
- Contribution to journal › Letter
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
- 2014
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.
(
- Contribution to journal › Article
- 2013
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
-
Mark
Variability of computational fluid dynamics solutions for pressure and flow in a giant aneurysm : the ASME 2012 Summer Bioengineering Conference CFD Challenge
(
- Contribution to journal › Article
-
Mark
The genomic landscape of hypodiploid acute lymphoblastic leukemia
(
- Contribution to journal › Article
- 2012
-
Mark
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al Reply
(
- Contribution to journal › Letter
-
Mark
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
- 2011
-
Mark
Long-term patient survival in ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2010
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
- 2009
-
Mark
Optimizing the Birmingham vasculitis activity scale to predict end-stage renal disease and death in ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
The association between relapses of ANCA-associated vasculitis and the composite endpoint of end-stage renal disease or death
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictors of long-term (>= 5 year) renal survival in 535 patients with ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction
(
- Contribution to journal › Article